Etzer Darout
Stock Analyst at BMO Capital
(3.17)
# 1,178
Out of 4,755 analysts
104
Total ratings
32.47%
Success rate
6.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $2.70 | +11.11% | 3 | Feb 11, 2025 | |
IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.32 | +51.52% | 2 | Jan 10, 2025 | |
EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $34.92 | +14.55% | 3 | Dec 20, 2024 | |
TRML Tourmaline Bio | Initiates: Outperform | $50 | $13.03 | +283.73% | 1 | Dec 6, 2024 | |
PTGX Protagonist Therapeutics | Initiates: Outperform | $62 | $36.81 | +68.43% | 1 | Dec 6, 2024 | |
NRIX Nurix Therapeutics | Initiates: Outperform | $35 | $16.83 | +108.02% | 1 | Dec 6, 2024 | |
KYMR Kymera Therapeutics | Initiates: Market Perform | $55 | $34.24 | +60.63% | 1 | Dec 6, 2024 | |
JSPR Jasper Therapeutics | Initiates: Outperform | $63 | $5.19 | +1,113.87% | 1 | Dec 6, 2024 | |
ARVN Arvinas | Maintains: Outperform | $90 → $88 | $18.83 | +367.46% | 2 | Nov 20, 2024 | |
ACRV Acrivon Therapeutics | Maintains: Outperform | $28 → $27 | $5.10 | +429.41% | 7 | Nov 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $81.14 | +65.15% | 6 | Nov 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $16.16 | +110.40% | 5 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $19.05 | +151.97% | 3 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $106.87 | +12.29% | 3 | Oct 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $35.93 | +5.76% | 3 | Oct 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 → $26 | $4.28 | +508.19% | 4 | Sep 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $5.80 | +331.41% | 6 | Aug 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $2.38 | +110.08% | 9 | Aug 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $3.23 | +520.16% | 3 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $40.05 | +127.22% | 5 | Jun 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.20 | +400.00% | 7 | May 10, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.79 | +356.98% | 10 | May 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $123 → $122 | $114.53 | +6.52% | 3 | May 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $73.62 | +11.38% | 4 | Apr 26, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.53 | +374.82% | 2 | Sep 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.62 | +238.08% | 2 | Apr 25, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $266.94 | -36.32% | 2 | Feb 3, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $84 | $7.59 | +1,006.72% | 1 | Jul 12, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $50.33 | +7.30% | 1 | Feb 26, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $50.22 | -24.33% | 2 | Sep 9, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $2.17 | +2,301.85% | 1 | Mar 28, 2018 |
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.70
Upside: +11.11%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.32
Upside: +51.52%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $34.92
Upside: +14.55%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $13.03
Upside: +283.73%
Protagonist Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $62
Current: $36.81
Upside: +68.43%
Nurix Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $16.83
Upside: +108.02%
Kymera Therapeutics
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $34.24
Upside: +60.63%
Jasper Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $5.19
Upside: +1,113.87%
Arvinas
Nov 20, 2024
Maintains: Outperform
Price Target: $90 → $88
Current: $18.83
Upside: +367.46%
Acrivon Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $5.10
Upside: +429.41%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $81.14
Upside: +65.15%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $16.16
Upside: +110.40%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $19.05
Upside: +151.97%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $106.87
Upside: +12.29%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $35.93
Upside: +5.76%
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $4.28
Upside: +508.19%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $5.80
Upside: +331.41%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $2.38
Upside: +110.08%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.23
Upside: +520.16%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $40.05
Upside: +127.22%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.20
Upside: +400.00%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.79
Upside: +356.98%
May 7, 2024
Maintains: Outperform
Price Target: $123 → $122
Current: $114.53
Upside: +6.52%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $73.62
Upside: +11.38%
Sep 1, 2023
Reiterates: Buy
Price Target: $12
Current: $2.53
Upside: +374.82%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.62
Upside: +238.08%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $266.94
Upside: -36.32%
Jul 12, 2021
Initiates: Buy
Price Target: $84
Current: $7.59
Upside: +1,006.72%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $50.33
Upside: +7.30%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $50.22
Upside: -24.33%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $2.17
Upside: +2,301.85%